Evidence map›Paper›PMID 40895861›Full record

ArticleCureus2025

Late-Onset Angioimmunoblastic T-cell Lymphoma During Nivolumab Treatment for Melanoma.

Akihiro Miyashita, Taichi Murao, Yuji Shimura, Haruya Okamoto, Hiroaki Nagata, Akio Onishi, Takahiro Fujino, Shinsuke Mizutani, Taku Tsukamoto, Junya Kuroda

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Akihiro MiyashitaDepartment of Internal Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, USA.
Taichi MuraoDepartment of Hematology, Panasonic Health Insurance Organization Matsushita Memorial Hospital, Osaka, JPN.
Yuji ShimuraDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, JPN.
Haruya OkamotoDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, JPN.
Hiroaki NagataDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, JPN.
Akio OnishiDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, JPN.
Takahiro FujinoDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, JPN.
Shinsuke MizutaniDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, JPN.
Taku TsukamotoDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, JPN.
Junya KurodaDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) are innovative immunotherapeutic agents used to treat various types of cancer by enhancing T-cell-mediated antitumor activity. These agents have distinct adverse events, known as immune-related adverse events, which can affect multiple organ systems and typically occur within a year after initiating ICI therapy. Another concern regarding ICI therapy is the potential development of T-cell lymphomas due to prolonged activation of T-cell activity. We report the case of a 56-year-old female who was treated with nivolumab for metastatic melanoma for over seven years and subsequently developed concurrent angioimmunoblastic T-cell lymphoma and ICI-related cholangitis. This case highlights the importance of careful monitoring for the emergence of late-onset T-cell lymphoma in patients undergoing long-term ICI therapy.

Indexed as

angioimmunoblastic t-cell lymphomacholangitisimmune checkpoint inhibitorsimmune-related adverse eventsnivolumab

Identifiers

PMID40895861
PMCPMC12395391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.